Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review.
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review.
复制标题
DOI：
10.3389/fpsyt.2022.917199
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
Cleare, Anthony J.
中科院分区：
文献类型：
--
作者：
Ko, Kwonmok;Knight, Gemma;Rucker, James J.;Cleare, Anthony J.
关键词：
神秘体验是影响迷幻治疗效果的潜在心理机制。它包括海洋无边，自我溶解和普遍相互联系等特征，这些特征与症状减轻和生活质量改善密切相关。在这篇综述中，分析了12项利用psilocybin，ayahuasca或氯胺酮进行迷幻治疗的研究，以了解神秘体验与症状减轻之间的关联，这些研究涉及癌症相关的困扰，物质使用障碍和抑郁症等领域，包括治疗抵抗。12个中的10个建立了相关性、中介和/或预测的显著关联。然而，大多数研究都受到样本量小和缺乏多样性（性别，民族，种族，教育和社会经济）的限制，这在这个新兴领域很常见。此外，12项研究中有6项为开放标签设计，因此易受偏倚影响。未来此类性质的研究应考虑更大的样本量和更大的多样性，从而通过使用随机设计来代表。需要对神秘体验的性质进行更深入的探索，包括强度的预测因素，以最大限度地提高其对治疗结果的积极影响，并最大限度地减少伴随的焦虑。系统综述注册：PROSPERO，标识符CRD 42021261752。
The mystical experience is a potential psychological mechanism to influence outcome in psychedelic therapy. It includes features such as oceanic boundlessness, ego dissolution, and universal interconnectedness, which have been closely linked to both symptom reduction and improved quality of life. In this review, 12 studies of psychedelic therapy utilizing psilocybin, ayahuasca, or ketamine were analyzed for association between mystical experience and symptom reduction, in areas as diverse as cancer-related distress, substance use disorder, and depressive disorders to include treatment-resistant. Ten of the twelve established a significant association of correlation, mediation, and/or prediction. A majority of the studies are limited, however, by their small sample size and lack of diversity (gender, ethnic, racial, educational, and socioeconomic), common in this newly re-emerging field. Further, 6 out of 12 studies were open-label in design and therefore susceptible to bias. Future studies of this nature should consider a larger sample size with greater diversity and thus representation by use of randomized design. More in-depth exploration into the nature of mystical experience is needed, including predictors of intensity, in order to maximize its positive effects on treatment outcome benefits and minimize concomitant anxiety. Systematic Review Registration: PROSPERO, identifier CRD42021261752.
登录
查看更多内容
DOI：
10.1177/0269881114548296
发表时间：
2014-11
期刊：
Journal of psychopharmacology (Oxford, England)
影响因子：
--
作者：
Johnson MW;Garcia-Romeu A;Cosimano MP;Griffiths RR
通讯作者：
Griffiths RR
影响因子：
4.3
作者：
Dittrich, A
通讯作者：
Dittrich, A
影响因子：
4.7
作者：
Kuypers, K. P. C.
通讯作者：
Kuypers, K. P. C.
影响因子：
4.1
作者：
Agin-Liebes, Gabrielle, I;Malone, Tara;Ross, Stephen
通讯作者：
Ross, Stephen
将神秘体验与自然迷幻科学相调和：回复桑德斯和齐尔曼斯。
影响因子：
--
作者：
Jylkkä J
通讯作者：
Jylkkä J